Cost-Effectiveness of SAPIEN 3 Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in German Severe Aortic Stenosis Patients at Low Surgical Mortality Risk
ConclusionsTAVI with SAPIEN 3 appears to be a clinically meaningful, cost-effective treatment option over SAVR for patients with severe symptomatic aortic stenosis and low risk for surgical mortality in Germany.Clinical Trial Registration Numberwww.clinicaltrials.gov identifier: NCT02675114.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Aortic Stenosis | Cardiology | Cardiovascular | Clinical Trials | Drugs & Pharmacology | Germany Health | Health Insurance | Healthcare Costs | Heart | Heart Valve Surgery | Insurance | Stroke | Study